

Reactie Lupin, fabrikant van NaMuscla®

Lupin said that following approval from the EMA for NaMuscla, the company has been preparing documentation on the medicine for submission to reimbursement authorities in Europe including in the Netherlands, so doesn't have any information on pricing in the Dutch market yet.